Rationale, design, and organization of the diastolic heart failure assessment study in Tohoku District (DIAST)

Circulation Journal

Volumn 68, Issue 7, 2004, Pages 660-664

  Shinozaki, Tsuyoshi ^a   Watanabe, Jun ^a   Kikuchi, Junichi ^b   Tamaki, Kenji ^c   Hoshi, Nobuo ^d   Hayashi, Masato ^e   Onodera, Yukio ^f   Hiramoto, Tetsuya ^g   Ikeda, Jun ^h   Sakuma, Masahito ^a   Fukuchi, Mitsumasa ⁱ   Sugi, Masafumi ^j   Kagaya, Yutaka ^a   Shirato, Kunio ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Towada City Hospital   (Japan)

^c Iwate Prefectural Central Hospital   (Japan)

^d Iwate Prefectural Miyako Hospital   (Japan)

^e Hiraka General Hospital   (Japan)

^f Ogachi Central Hospital   (Japan)

^g SENDAI CITY MEDICAL CENTER   (Japan)

^h Sendai Red Cross Hospital   (Japan)

ⁱ TOHOKU ROSAI HOSPITAL   (Japan)

^j Iwaki Kyoritu General Hospital   (Japan)

more..

Author keywords

Beta blocker; Carvedilol; Diastolic heart failure; Morbidity; Mortality

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; NEUROHORMONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC HEART FAILURE; DISEASE EXACERBATION; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE VARIABILITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SLEEP APNEA SYNDROME; TREATMENT OUTCOME;

DIASTOLE; ETHICS, MEDICAL; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; JAPAN; PATIENT READMISSION; SURVIVAL ANALYSIS;

EID: 3142557823     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.660     Document Type: Article

References (37)

1. Levy D, Kenchaiah S, Larson MG, Bejamin EJ, Kupka MJ, Ho KKL, et al. Long-term trends in the incidence of and survival with heart failure. New Eng J Med 2002; 347: 1397-1402.
2. Kurmholz HM, Chen YT, Wang Y, Vaccarino V, Radfold MJ, Horwitz RI. Predictions of readmission among elderly survivors of admission with heart failure. Am Heart J 2000; 139: 72-77.
3. Koseki Y, Watanabe J, Shinozaki T, Sakuma M, Komaru T, Fukuchi M, et al. Characteristics and 1-year prognosis of medically treated patints with chronic heart failure in Japan: Chronic Heart Failure Analysis Registry in Tohoku District (CHART). Circ J 2003; 67: 431-436.
4. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the community: A study of all incident cases in Olmsted Country, Minnesota, in 1991. Circulation 1998; 98: 2282-2289.
5. Shinozaki T, Watanabe J, Takahashi T, Kagaya Y, Shirato K. BNP and atrial fibrillation predict the prognosis of patients with diastolic heart failure (abstract). Circ J 2003; 67(Suppl 1): 136.
6. McAlister FA, Teo KK, Taher M, Montague TJ, Humen D, Cheung L, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J 1999; 138: 87-94.
7. Senni M, Redfield MM. Heart failure with preserved systolic function: A different natural history? J Am Coll Cardiol 2001; 38: 1277-1282.
8. Vasan RS, Levy D. Defining diastolic heart failure. Circulation 2000; 101: 2118-2121.
9. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CAHRM-Preserved Trial. Lancet 2003; 362: 777-781.
10. Cleland JGF, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, et al. Perindopril for elderly people with chronic heart failure: The PEP-CHF study. Eur J Heart Fail 1999; 1: 211-217.
11. Shibata MC, Flather MD, Boehm M, Borbola J, Cohen-Solal A, Dumitrascu D, et al. Study of the effects of nevivolol intervention on outcomes and rehospitalisation in seniors with heart failure (SENIOR): Rationale and design. Int J Cardiol 2002; 86: 77-85.
12. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288: 2144-2150.
13. Briest W, Holzl A, Rassler B, Deten A, Leicht M, Baba HA, et al. Cardiac remodeling after long-term norepinephrine treatment in rats. Cardiovasc Res 2001; 52: 265-273.
14. Barth W, Deten A, Bauer M, Reinohs M, Leicht M, Zimmer HG. Differential remodeling of the left and right heart after norepinephrine treatments in rats: Studies on cytokines and collagen. J Mol Cell Cardiol 2000; 32: 273-284.
15. Bhambi B, Eghbali M. Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment. Am J Pathol 1991; 139: 1131-1142.
16. Wong VV, Laping NJ, Nelson AH, Contino LC, Olson BA, Gygielko E, et al. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF-β expression. Br J Pharmacol 2001; 134: 977-984.
17. Koitabashi N, Arai M, Hara S, Tomaru K, Takizawa T, Watanabe A, et al. Carvedilol down-regulates the gene expression of connective tissue growth factor in neonatal rat cardiac myocytes and non-myocytes (abstract). J Card Fail 2003; 9(Suppl): S188.
18. Uemura S, Iwama H, Yoshitomi K, Kawata Y, Takaoka M, Saito Y. β-2 adrenergic receptor antagonism inhibits matrix metalloprotease-9 activation in human endothelial cells (abstract). J Card Fail 2003; 9(Suppl): S121.
19. Grimm D, Huber M, Jabusch HC, Shakibaei M, Fredersdorf S, Paul M, et al. Extracellalar matrix proteins in cardiac fibroblasts derived from rat heart with chronic pressure overload: Effects of β-receptor blockade. J Mol Cell Cardiol 2001; 33: 487-501.
20. Sia YT, Parker TG, Tsoporis JN, Liu P, Adam P, Rouleau JL. Long-term effects of carvedilol on left ventricular function, remodeling and expression of cardiac cytokines after large myocardial infarction in the rat. J Cardiovasc Pharmacol 2002; 39: 73-87.
21. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell 2000; 101: 365-376.
22. Doi M, Yano M, Kobayashi S, Kohno M, Tokuhisa T, Okuda S, et al. Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor. Circulation 2002; 105: 1374-1379.
23. Plank Dm, Yatani A, Honda R, Witt S, Glascock B, Lalli J, et al. Calcium dynamics in the failing heart: Restoration by b-adrenergic receptor blockade. Am J Physiol 2003; 285: H305-H315.
24. Aizawa T, Ishizaka N, Usual S, Hash N, Ohno M, Nagy R. Angiotensin II and catecholamines increase plasma level of 8-epi-prostaglandin F (2α) with different pressor dependencies in rats. Hypertension 2002; 39: 149-154.
25. Bonnefont-Rousselot D, Mahmoudi A, Mougenot N, Varoquaux O, Le Nahour G, Fouret P, et al. Catecholamine effects on cardiac remodeling, oxidative stress and fibrosis in experimental heart failure. Redox Rep 2002; 7: 145-151.
26. Qin F, Rounds NK, Mao W, Kawai K, Liang CS. Antioxidant vitamins prevent cardiomyocyte apoptosis produced by norepinephrine infusion in ferrets. Cardiovasc Res 2001; 51: 736-748.
27. Date M, Morita T, Yamashita N, Nishida K, Yamaguchi O, Higuchi Y, et al. The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in vivo murine pressure-overload model. J Am Coll Cardiol 2002; 39: 907-912.
28. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: Role of oxidative stress. Cir Res 2000; 87: 392-398.
29. Qin F, Shite J, Liang CS. Antioxidants attenuate myocyte apoptosis and improve cardiac function in CHF: Association with changes in MAPK pathway. Am J Physiol 2003; 285: H822-H832.
30. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002: 105: 2867-2871.
31. Chen HH, Lainchbury JG, Senni M, Bailey KR, Redfield MM. Diastolic heart failure in the community: Clinical profiles, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail 2002; 8: 279-287.
32. Dahlstroem U. Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur J Heart Fail 2004; 6: 281-297.
33. Palazzuoli A, Carrera A, Calabria P, Puccetti L, Pastrorelli M, Pasqui AL, et al. Effects of carvedilol therapy on restrictive diastolic filling patter in chronic heart failure. Am Heart J 2004; 147: E2.
34. Takeda Y, Fukutomi T, Suzuki S, Takeda Y, Fukutomi T, Suzuki S, et al. Effects of carvedilol on plasma brain natriuretic peptide concentration in patients with isolated diastolic heart failure (abstract). Circ J 2003; 67(Suppl I): 469.
35. Mckee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med 1971; 285: 1441-1446.
36. Sasayama S, Asanoi H, Kihara Y, Yokawa S, Terada Y, Yoshida S, et al. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart Vessels 1994; 9: 113-120.
37. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004; 147: 324-330.